Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (411-420 of 477) with videos related to

Pageof 48
Sort By:
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyLisa R Jewett, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAITAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
Arthritis and Rheumatism|September 30, 2008
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trialAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
The Journal of Rheumatology|January 17, 2019
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT InitiativeSabrina M Nielsen, Peter Tugwell, Maarten P T de Wit, et al.
Expert Review of Clinical Immunology|June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposiumIvan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Clinical Rheumatology|April 27, 2018
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional studyDimitrios A Pappas, Fredrik Nyberg, Joel M Kremer, et al.
Annals of the Rheumatic Diseases|October 15, 2020
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working groupSabrina Mai Nielsen, Marianne Uggen Rasmussen, Maarten Boers, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 48

Showing results (411-420 of 477) with videos related to

Sort By:
Pageof 48
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyLisa R Jewett, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAITAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
Arthritis and Rheumatism|September 30, 2008
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trialAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
The Journal of Rheumatology|January 17, 2019
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT InitiativeSabrina M Nielsen, Peter Tugwell, Maarten P T de Wit, et al.
Expert Review of Clinical Immunology|June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposiumIvan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Clinical Rheumatology|April 27, 2018
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional studyDimitrios A Pappas, Fredrik Nyberg, Joel M Kremer, et al.
Annals of the Rheumatic Diseases|October 15, 2020
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working groupSabrina Mai Nielsen, Marianne Uggen Rasmussen, Maarten Boers, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 48